A two-year follow-up of neonates with presumed sepsis treated with recombinant human granulocyte colony-stimulating factor during the first week of life.
We have previously reported that recombinant human granulocyte colony-stimulating factor was well tolerated and resulted in sustained neutrophilia and improvement of neutrophil functions in newborn infants with presumed sepsis. We now report a 2-year follow-up on 21 of the initial cohort of 28 patients. Treatment with recombinant human granulocyte colony-stimulating factor in neonates with presumed sepsis was not associated with any long-term adverse hematologic, immunologic, or developmental effects.
Rosenthal
J
J
Division of Hematology/Oncology, Children's Hospital of Orange County, Orange, California 92668, USA.
Healey
T
T
Ellis
R
R
Gillan
E
E
Cairo
M S
MS
D001772:Blood Cell Count; D002657:Child Development / Q000502:physiology; D005500:Follow-Up Studies; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007136:Immunoglobulins / Q000097:blood; D007223:Infant; D007231:Infant, Newborn; D011994:Recombinant Proteins / Q000627:therapeutic use; D018805:Sepsis / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome
D007136:Immunoglobulins; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor